Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer
J Zhang, J Yu, X Sun, X Meng - Cancer letters, 2014 - Elsevier
Brain metastases (BM) are common and disastrous occurrence in patients with non-small
cell lung cancer (NSCLC). Currently increasing studies suggest remarkable efficacy and …
cell lung cancer (NSCLC). Currently increasing studies suggest remarkable efficacy and …
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases
SM Lee, CR Lewanski, N Counsell… - JNCI: Journal of the …, 2014 - academic.oup.com
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …
[PDF][PDF] High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on …
JL Kuiper, DA Heideman, E Thunnissen, AW van Wijk… - Eur J …, 2014 - academia.edu
Resistance to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)-
patients with an epidermal growth factor (EGFR) mutation is a major clinical problem …
patients with an epidermal growth factor (EGFR) mutation is a major clinical problem …
Long term therapeutic plan for patients with non-small cell lung cancer harboring EGFR mutation
SH Jang - Tuberculosis and Respiratory Diseases, 2014 - synapse.koreamed.org
Non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) sensitizing
mutations has a distinct disease entity. Patients with this cancer have better prognosis, and …
mutations has a distinct disease entity. Patients with this cancer have better prognosis, and …
非小细胞肺癌脑转移药物治疗的研究进展
蔡忠福， 欧阳学农， 余宗阳 - 临床肿瘤学杂志, 2014 - manu65.magtech.com.cn
非小细胞肺癌(NSCLC) 是最常见的恶性肿瘤之一, 也是导致癌症死亡的主要原因, 其疗效欠佳,
预后差, 尤其是伴有脑转移患者. NSCLC 伴脑转移患者生活质量差, 预后不良 …
预后差, 尤其是伴有脑转移患者. NSCLC 伴脑转移患者生活质量差, 预后不良 …
Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor
H Zheng, Q Wang, H Shi, H Zhang, F Hu… - Thoracic Cancer, 2014 - Wiley Online Library
Many studies have illustrated that two types of mutation–deletions in exon 19 and a point
mutation in exon 21 (L858R)–have been reported to comprise up to 90% of all activating …
mutation in exon 21 (L858R)–have been reported to comprise up to 90% of all activating …
[PDF][PDF] Journal of Thoracic Oncology Publish Ahead of Print
MD Märten, RM Huber, NJ Dickgreber - academia.edu
Introduction: Afatinib is an effective first-line treatment in patients with epidermal growth
factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has shown activity …
factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has shown activity …